CN117815135A - 含有北美乔松树皮提取物的美白淡斑组合物 - Google Patents
含有北美乔松树皮提取物的美白淡斑组合物 Download PDFInfo
- Publication number
- CN117815135A CN117815135A CN202410007738.4A CN202410007738A CN117815135A CN 117815135 A CN117815135 A CN 117815135A CN 202410007738 A CN202410007738 A CN 202410007738A CN 117815135 A CN117815135 A CN 117815135A
- Authority
- CN
- China
- Prior art keywords
- whitening
- extract
- skin
- bark
- spot
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002087 whitening effect Effects 0.000 title claims abstract description 37
- 239000000284 extract Substances 0.000 title claims abstract description 27
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- 208000003351 Melanosis Diseases 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 239000002537 cosmetic Substances 0.000 claims abstract description 11
- 230000000694 effects Effects 0.000 claims description 17
- 102000003425 Tyrosinase Human genes 0.000 claims description 9
- 108060008724 Tyrosinase Proteins 0.000 claims description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 4
- 239000003974 emollient agent Substances 0.000 claims description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 4
- 206010008570 Chloasma Diseases 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 2
- 229960000458 allantoin Drugs 0.000 claims description 2
- 239000002199 base oil Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 2
- 229920005862 polyol Polymers 0.000 claims description 2
- 150000003077 polyols Chemical class 0.000 claims description 2
- 229940032094 squalane Drugs 0.000 claims description 2
- 235000013311 vegetables Nutrition 0.000 claims description 2
- 240000007263 Pinus koraiensis Species 0.000 claims 4
- 235000011615 Pinus koraiensis Nutrition 0.000 claims 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 abstract description 12
- 239000002126 C01EB10 - Adenosine Substances 0.000 abstract description 6
- KNFLNGRLKALWRF-LDXSYGEZSA-N CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)CC1=CC=CC=C1 Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)CC1=CC=CC=C1 KNFLNGRLKALWRF-LDXSYGEZSA-N 0.000 abstract description 6
- 229960005305 adenosine Drugs 0.000 abstract description 6
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 abstract description 6
- 229960000401 tranexamic acid Drugs 0.000 abstract description 6
- 230000008099 melanin synthesis Effects 0.000 abstract description 5
- 230000009471 action Effects 0.000 abstract description 4
- 239000013535 sea water Substances 0.000 abstract description 4
- HIXYEIRACBUSON-FJXQXJEOSA-N (2s)-2-(3-aminopropanoylamino)-3-(1h-imidazol-5-yl)propanoic acid;hydrochloride Chemical compound Cl.NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 HIXYEIRACBUSON-FJXQXJEOSA-N 0.000 abstract description 3
- 108010087806 Carnosine Proteins 0.000 abstract description 3
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 3
- 229940070763 carnosine hydrochloride Drugs 0.000 abstract description 3
- 235000008331 Pinus X rigitaeda Nutrition 0.000 abstract description 2
- 235000011613 Pinus brutia Nutrition 0.000 abstract description 2
- 241000018646 Pinus brutia Species 0.000 abstract description 2
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 abstract description 2
- 230000003712 anti-aging effect Effects 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 22
- 238000012360 testing method Methods 0.000 description 16
- 238000002835 absorbance Methods 0.000 description 15
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 12
- 239000000047 product Substances 0.000 description 10
- 239000000523 sample Substances 0.000 description 7
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000005562 fading Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000036564 melanin content Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000000419 plant extract Substances 0.000 description 3
- -1 radix angelicae Chemical compound 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000007790 scraping Methods 0.000 description 2
- 239000011265 semifinished product Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 241000213006 Angelica dahurica Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000235342 Saccharomycetes Species 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 238000002792 antioxidant assay Methods 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 210000002780 melanosome Anatomy 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000037393 skin firmness Effects 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9755—Gymnosperms [Coniferophyta]
- A61K8/9767—Pinaceae [Pine family], e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Rheumatology (AREA)
- Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
Abstract
本发明属于化妆用配制品技术领域，具体涉及了一种含有北美乔松树皮提取物的美白淡斑组合物。本发明包括组分：传明酸、烟酰胺、腺苷、脱羧肌肽盐酸盐、九肽‑1、北美乔松树皮提取物、海水仙提取物。本发明提供的美白淡斑组合物通过不同的对黑色素的生产路径的不同节点进行作用，能从多个方面改善皮肤的色泽和质感。同时还具有一定的抗衰老、抗炎效果。
Description
技术领域
本发明属于化妆用配制品技术领域，具体涉及一种含有北美乔松树皮提取物的美白淡斑组合物。
背景技术
美白护肤品是指能够改善肤色，减少色斑，提高肌肤亮度和透明感的护肤品。美白护肤品的主要作用机制是抑制黑色素的生成和转运，促进黑色素的分解和排出，从而减少皮肤中的黑色素含量，使肤色更均匀、透亮。
目前，市场上的美白护肤品主要包括化学美白和植物美白两大类。化学美白是指使用一些化学合成的美白成分，如对苯二酚、曲酸、鞣花酸、维生素C等，这些成分可以从源头抑制黑色素的形成，或者破坏已经生成的黑色素。植物美白是指使用一些天然的植物提取物，如熊果素、白芷、甘草、桑白皮等，这些提取物可以通过抗氧化、抗炎、抑菌等多种途径，影响黑色素的代谢和分布。
然而，现有的美白护肤品仍然存在一些不足之处，比如对苯二酚、白芷等由于安全性问题已经被禁用或者严格限用。而植物提取物有可能出现效果未经验证，难以证明的问题；同时还可能会受到植物本身的品质、提取工艺、保存条件等因素的影响，导致美白效果不稳定或不可控。
发明内容
本发明提供了一种含有北美乔松树皮提取物的美白淡斑组合物，在于通过传统有效的美白成分与植物提取物组合，得到一种效果进一步的美白组合。
一种含有北美乔松树皮提取物的美白淡斑组合物，以质量份计算包括以下组分：
特别优选的，以质量份计算包括以下组分：
优选的，美白淡斑组合物还包括润肤剂。
所述润肤剂包括以下成分中的至少一种：
甘油、尿囊素、多元醇、角鲨烷、植物基础油、透明质酸及其衍生物。
前述含有北美乔松树皮提取物的美白淡斑组合物的制备方法，将各组分和适量的水混合，然后搅拌、均质至完全溶解。
本发明还提供前述含有北美乔松树皮提取物的美白淡斑组合物在制备皮肤外用剂中的应用。
所述皮肤外用剂为用于提亮肤色和/或淡化黄褐斑。
所述皮肤外用剂通过抑制酪氨酸酶的活性提亮肤色。
所述皮肤外用剂为淋洗类化妆品或/和驻留类化妆品。
所述化妆品为淋洗类化妆品或/和驻留类化妆品，包括但不限于洁面产品、爽肤水、乳液、面膜、面霜和精华液等。
本发明中：
传明酸(凝血酸)是一种蛋白酶抑制剂，可以抑制黑色素的生成。
烟酰胺可以抑制黑色素小体的转移。
腺苷可以抑制黑色素细胞活性。
九肽-1可以抑制酪氨酸酶活性。
除了美白以外，传明酸还能抗炎、修复屏障、收缩血管扩张，对黄褐斑和炎症后色沉有一定的改善作用。烟酰胺还能增强皮肤的保湿能力和抵抗力，预防老化和粉刺。腺苷、脱羧肌肽盐酸盐和九肽-1能刺激胶原蛋白和弹力蛋白的合成，增加皮肤的弹性和紧致度。腺苷还能抗氧化，保护皮肤免受自由基的损伤。
北美乔松树皮提取物和海水仙提取物有一定的美白和抗氧化作用，能抑制酪氨酸酶的活性，减少黑色素的形成。它们还能舒缓皮肤的敏感和炎症，增强皮肤的屏障功能。本发明发现，北美乔松树皮提取物和海水仙提取物对传明酸、烟酰胺、腺苷、九肽-1的美白作用具有协同效应，在同等用量下比单一的成分美白效果更加。
北美乔松树皮提取物和海水仙提取物由于是粉末状的提取物，不含水分故起效浓度很低，只需要少量添加也能起效。相应的，九肽-1、脱羧肌肽盐酸盐也具有很低的起效浓度。
本发明提供的美白淡斑组合物通过不同的对黑色素的生产路径的不同节点进行作用，能从多个方面改善皮肤的色泽和质感。同时还具有一定的抗衰老、抗炎效果。
具体实施方式
为了更好地理解本发明，下面结合具体序号对本发明作进一步的描述，其中序号中使用的术语是为了描述特定的具体实施方案，不构成对本发明保护范围的限制。
序号中，所使用的实验方法如无特殊说明，均为常规方法，所用的材料、试剂等，如无特殊说明，均可从商业途径得到。
如无特别说明，％、百分比均默认为质量百分比。
本发明所使用部分原料来源如下表1：
表1
美白淡斑组合物的制备
美白淡斑组合物的制备方法包括以下步骤：
(1)A组分搅拌加热至85℃，搅拌、均质至完全溶解，保温20分钟，备用；
(2)降温至65℃，加入预先溶解好的B、C组分，搅拌至完全溶解；
(3)降温至38℃，依次加入D。E组分各原料，搅拌至完全溶解；
(4)半成品的检验，检验合格后出料。
原料配比按表2-1、表2-2所示。
表2-1美白淡斑组合物配比
表2-2美白淡斑组合物配比
注：表2-1、表2-2中“-”表示未添加；表2-1、表2-2中“Ultrez 20Polymer”是指丙烯酸(酯)类/C10-30烷醇丙烯酸酯交联聚合物。
性能测试
(一)样品稳定性测试
1、耐热测试：恒温培养箱调节到40℃，将前述制取的十个样品，每个实施例取三支装于透明玻璃瓶中，装样量为20ml/瓶，封口后置于恒温培养箱内，2个月后取出，恢复至室温，观察外观变化。
2、耐寒测试：恒温培养箱调节到-10℃，将前述制取的十个样品，每个实施例取三支装于透明玻璃瓶中，装样量为20ml/瓶，封口后置于恒温培养箱内，2个月后取出，恢复至室温，观察外观变化。
3、常温测试：将前述制取的十个样品，每个实施例取三支装于透明玻璃瓶中，装样量为20ml/瓶，封口后常温下放置2个月后，观察外观变化。
耐热测试、耐寒测试、常温测试均未观察到析出、沉淀等现象，保持原来外观。
(二)过敏性测试
将获得的序号1-5的5组成品参照《2022化妆品安全技术规范》中的人体皮肤斑贴试验；
皮肤封闭型斑贴试验的方法为：选择年龄为18-60周岁的人员30名，选用面积不超过50mm2、深度约1mm的合格斑试器材，取用0.020mL上述制备的成品放入斑贴试器小室内，对照孔为空白对照(不置任何物质)，将加有成品的斑试器用低致敏胶带贴敷于受试者的前臂曲侧，用手掌轻压使之均匀地贴敷于皮肤上，持续24h。分别于去除成品后30min(待压痕消失后)、24h和48h标准观察皮肤反应，并记录观察结果；每个受试者均测量5组成品和对照孔。
所有受试者反应程度为“-”，0级反应；即阴性反应，没有出现过敏现象。
(三)安全性测试
根据《化妆品安全技术规范2022年版》(征求意见稿)中的卫生化学检验方法部分与微生物检验方法部分，对所有序号1-10的样品的汞、铅、砷、镉、霉菌与酵母菌总数、耐热大肠菌群、铜绿假单胞菌群、金黄色葡萄球菌进行检测，均符合对应指标标准要求。
(四)酪氨酸酶活性以及黑色素合成抑制实验
测试样品：前述制备的1-10号序号的样品
酪氨酸酶活性抑制试验：取对数生长期的小鼠黑色素瘤B16细胞，接种于6孔细胞培养板，培养过夜。分别加入终体积分数为2％的受试样品，以未处理组作细胞对照组，每组2个复孔。培养48h后用PBS(磷酸盐平衡生理盐水)洗涤1次，每孔加入100μL裂解液，刮取收集细胞，离心取上清液。取50μL细胞上清液至96孔板，再加入50μL1％L-多巴溶液，于37℃孵育1h，M3读板仪于475nm处读取吸光度值。
相对酪氨酸酶活性(％)＝(测定孔吸光度值-空白对照组吸光度值)/(细胞对照组吸光度值-空白对照组吸光度值)×100％。
黑色素合成抑制实验：取对数生长期的小鼠黑色素瘤B16细胞，接种于T25细胞培养瓶，培养过夜。分别加入终体积分数为1％的受试样品，以未处理组作为细胞对照组。培养48h后用PBS洗涤1次，加入1mL的1mol/LNaOH溶液，刮取收集细胞，放入80℃水浴中30min，取上清液加入96孔板，M3读板仪于475nm处读取吸光度值。
相对黑色素含量(％)＝(测定孔吸光度值-空白对照组吸光度值)/(细胞对照组吸光度值-空白对照组吸光度值)×100％。
酪氨酸酶活性以及黑色素合成抑制实验结果如表3所示，其中对照组的酪氨酸酶活性为100％，对照组的黑色素含量为100％。
表3相对络氨酸酶活性
| 序号 | 相对络氨酸酶活性(％) | 相对黑色素含量(％) |
| 1 | 30.4 | 35.0 |
| 2 | 31.1 | 35.7 |
| 3 | 29.3 | 33.7 |
| 4 | 29.7 | 34.2 |
| 5 | 28.1 | 32.3 |
| 6 | 33.4 | 38.4 |
| 7 | 32.4 | 37.3 |
| 8 | 38.2 | 43.9 |
| 9 | 44.3 | 50.9 |
| 10 | 36.8 | 42.3 |
从表3可以看到，序号3的效果最佳；序号6、7、8、9、10的结果显示，当缺少海水仙提取物、北美乔松树皮提取物、传明酸、酰胺、腺苷和九肽-1时，都会对美白效果有一定的降低。
(五)细胞抗氧化测试
实验材料：二苯基苦基苯肼自由基(简称：DPPH，Sigma公司，美国)；
du800紫外可见分光光度计(Beckman公司，美国)；
受试物共计10组，样品溶液为上述制备的样品(无需稀释)。
实验方法：取0.2mL样品溶液，加入2mL的60μmol/L的DPPH溶液混匀，放置30min，以原溶剂调零点，在517nm处测起吸光度为Ai；同法0.2mL无水乙醇溶剂与2mL DPPH溶液混匀测定吸光度极为Ac；0.2mL样品溶液与2mL无水乙醇溶剂混匀测定吸光度极为Aj。按下述公式计算其自由基清除率；结果如表4所示。
清除率(％)＝[1-(Ai-Aj)/Ac]×100％
其中，Aj反应样品自身对吸光度的贡献；Ai样品对DPPH作用后的吸光度数值；Ac为DPPH本身在测定波长的吸收。
表4抗氧化测结果
| 序号 | 清除率(％) |
| 1 | 86.2 |
| 2 | 85.8 |
| 3 | 88.6 |
| 4 | 86.4 |
| 5 | 91.1 |
| 6 | 78.3 |
| 7 | 82.1 |
| 8 | 72.8 |
| 9 | 66.2 |
| 10 | 76.6 |
上述详细说明是针对本发明其中之一可行实施例的具体说明，该实施例并非用以限制本发明的专利范围，凡未脱离本发明所为的等效实施或变更，均应包含于本发明技术方案的范围内。
Claims (9)
1.一种含有北美乔松树皮提取物的美白淡斑组合物，其特征在于，以质量份计算包括以下组分：
2.根据权利要求1所述的含有北美乔松树皮提取物的美白淡斑组合物，其特征在于，以质量份计算包括以下组分：
3.根据权利要求1所述的含有北美乔松树皮提取物的美白淡斑组合物，其特征在于，还包括润肤剂。
4.根据权利要求3所述的含有北美乔松树皮提取物的美白淡斑组合物，其特征在于，所述润肤剂包括以下成分中的至少一种：
甘油、尿囊素、多元醇、角鲨烷、植物基础油、透明质酸及其衍生物。
5.权利要求1-4所述的含有北美乔松树皮提取物的美白淡斑组合物的制备方法，其特征在于，将各组分和适量的水混合，然后搅拌、均质至完全溶解。
6.权利要求1-4所述的含有北美乔松树皮提取物的美白淡斑组合物在制备皮肤外用剂中的应用。
7.根据权利要求6所述的应用，所述皮肤外用剂为用于提亮肤色和/或淡化黄褐斑。
8.根据权利要求7所述的应用，所述皮肤外用剂通过抑制酪氨酸酶的活性提亮肤色。
9.根据权利要求6所述的应用，所述皮肤外用剂为淋洗类化妆品或/和驻留类化妆品。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410007738.4A CN117815135A (zh) | 2024-01-03 | 2024-01-03 | 含有北美乔松树皮提取物的美白淡斑组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410007738.4A CN117815135A (zh) | 2024-01-03 | 2024-01-03 | 含有北美乔松树皮提取物的美白淡斑组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117815135A true CN117815135A (zh) | 2024-04-05 |
Family
ID=90509560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410007738.4A Pending CN117815135A (zh) | 2024-01-03 | 2024-01-03 | 含有北美乔松树皮提取物的美白淡斑组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117815135A (zh) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102366397A (zh) * | 2011-11-29 | 2012-03-07 | 宝健（中国）日用品有限公司 | 一种美白淡斑亮肤组合物、含有该组合物的护肤品及制备方法 |
| CN109662898A (zh) * | 2018-12-06 | 2019-04-23 | 上海益好纳米科技有限公司 | 一种新型固体护肤品及其制备方法 |
| CN109984950A (zh) * | 2018-12-06 | 2019-07-09 | 上海益好纳米科技有限公司 | 一系列免洗全吸收型纳米纤维功能面膜及其制备方法 |
| CN112386520A (zh) * | 2020-11-24 | 2021-02-23 | 西安润玉医疗科技有限公司 | 一种全面改善肤色的中胚层注射组合物及其制备方法 |
| CN112716828A (zh) * | 2021-01-20 | 2021-04-30 | 广州易和生物科技有限公司 | 一种具有皮肤美白淡斑作用的组合物及其护肤品 |
| CN117064828A (zh) * | 2023-09-01 | 2023-11-17 | 科丝美诗(中国)化妆品有限公司 | 一种均匀肤色美白组合物及其制备方法和应用 |
-
2024
- 2024-01-03 CN CN202410007738.4A patent/CN117815135A/zh active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102366397A (zh) * | 2011-11-29 | 2012-03-07 | 宝健（中国）日用品有限公司 | 一种美白淡斑亮肤组合物、含有该组合物的护肤品及制备方法 |
| CN109662898A (zh) * | 2018-12-06 | 2019-04-23 | 上海益好纳米科技有限公司 | 一种新型固体护肤品及其制备方法 |
| CN109984950A (zh) * | 2018-12-06 | 2019-07-09 | 上海益好纳米科技有限公司 | 一系列免洗全吸收型纳米纤维功能面膜及其制备方法 |
| CN112386520A (zh) * | 2020-11-24 | 2021-02-23 | 西安润玉医疗科技有限公司 | 一种全面改善肤色的中胚层注射组合物及其制备方法 |
| CN112716828A (zh) * | 2021-01-20 | 2021-04-30 | 广州易和生物科技有限公司 | 一种具有皮肤美白淡斑作用的组合物及其护肤品 |
| CN117064828A (zh) * | 2023-09-01 | 2023-11-17 | 科丝美诗(中国)化妆品有限公司 | 一种均匀肤色美白组合物及其制备方法和应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108619033B (zh) | 具有协同美白效果的美白护肤精华及其制备方法 | |
| CN105381007B (zh) | 具有美白功效的外用中药组合物、制剂及其制备方法和用途 | |
| KR20080001791A (ko) | 연교추출물을 함유하는 피부 주름개선용 화장료 조성물 | |
| CN109771351A (zh) | 一种美白淡斑组合物及其应用 | |
| CN109316478A (zh) | 一种尿石素a在制备抗衰老的药物、化妆品中的应用及药物、化妆品 | |
| Amnuaikit et al. | Formulation development and facial skin evaluation of serum containing jellose from tamarind seeds | |
| KR100521768B1 (ko) | 피부미백용 화장료 조성물 | |
| CN112826778A (zh) | 一种抑制黑色素合成的多肽及植物组合物 | |
| Song et al. | Lactobacillus plantarum fermented Laminaria japonica alleviates UVB-induced epidermal photoinflammation via the Keap-1/Nrf2 pathway | |
| CN111658587A (zh) | 胶原酶抑制剂组合物、抗衰水分露及其制备方法 | |
| CN115737709B (zh) | 一种生物发酵物及其制备方法和应用 | |
| CN115054556B (zh) | 一种修护光损伤的组合物及其应用 | |
| CN117815135A (zh) | 含有北美乔松树皮提取物的美白淡斑组合物 | |
| Tsai et al. | Djulis supplementation against oxidative stress and ultraviolet radiation‐induced cell damage: The influence of antioxidant status and aging of skin in healthy subjects | |
| CN113876833B (zh) | 白桑葚发酵物及其制备方法与用途 | |
| US20210177735A1 (en) | Cosmetic composition including curcuma aromatica salisb extract and elaeocarpus sylvestris var. ellipticus extract for blocking blue light | |
| CN116918701B (zh) | 细梗蔷薇愈伤组织培养基及提取物、制备方法和应用 | |
| Li et al. | Panax ginseng CA Meyer phenolic acid extract alleviates ultraviolet B‐irradiation‐induced photoaging in a hairless mouse skin Photodamage model | |
| KR100406124B1 (ko) | 자외선에 의해 증가하는 프로스타글란딘을 억제하는성분과 멜라닌 합성을 억제하는 성분을 동시에 함유하는미백 화장료 조성물 | |
| CN105168055B (zh) | 含有桂花苯乙醇总苷的美白淡斑化妆品及其制备方法 | |
| CN112716828A (zh) | 一种具有皮肤美白淡斑作用的组合物及其护肤品 | |
| He et al. | Dendrobium officinale flowers' topical extracts improve skin oxidative stress and aging | |
| CN109431911A (zh) | 美白保湿晶露及其制备方法和酪氨酸酶抑制剂 | |
| CN112656746B (zh) | 一种含射干根提取物的美白祛斑霜 | |
| CN115105455B (zh) | 一种具有抗糖化作用的多肽植物组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |